The short answer on tesamorelin dosage
The approved tesamorelin dose is 2 mg injected subcutaneously once daily for reducing excess visceral abdominal fat in adults with HIV‑associated lipodystrophy. This is a fixed dose (not weight‑based) and requires medical supervision and monitoring (for example IGF‑1 and glucose).
Outside of this indication, “protocols” you see online are off‑label. These should not be started or modified without a prescriber who can assess risks, interactions and lab values.
Approved dosing at a glance
- Indication: Reduction of excess abdominal visceral adipose tissue in adults with HIV‑associated lipodystrophy.
- Standard dose: 2 mg subcutaneously once daily, using rotating abdominal injection sites.
- Monitoring typically considered: IGF‑1 at baseline and periodically; glucose/HbA1c; watch for fluid retention, carpal tunnel‑like symptoms, and injection‑site reactions.
- Duration: Trials commonly evaluate 26–52 weeks. Visceral fat tends to rebound after stopping, so continuation is a clinical decision weighing benefits, side effects and lab values.
- Not a general weight‑loss medicine: Using tesamorelin for “belly fat” in the general population is off‑label and may carry additional risks.
Forms, strengths and storage basics
Tesamorelin is supplied as a lyophilised powder for injection that is reconstituted with diluent before use. Brand and compounded presentations can differ in:
- Vial strength (for example single‑vial presentations designed to deliver a 2 mg dose after reconstitution)
- Specified diluent volume and type
- Storage requirements before and after reconstitution
- Shelf life and in‑use stability
Always follow the instructions provided with your prescribed product. Do not copy reconstitution volumes or techniques you find online if they do not match your exact vial strength and label directions.
Popular protocol claims you’ll see online (and what to know)
- Timing (morning vs evening): Some claim evening dosing is better due to natural GH rhythms. Evidence for superior outcomes by timing is limited. Consistency matters; follow your prescriber.
- Fasted injections: A fasted state is sometimes recommended online. Clinical significance is uncertain; your prescriber can advise based on your glucose control and routine.
- Cycling: “8 weeks on / 4 weeks off” and similar cycles circulate online. The approved use is continuous daily dosing; cycles are off‑label and should consider symptom control, IGF‑1 and metabolic markers.
- Stacks with other GHRPs or GHRHs: Combining agents can raise IGF‑1 more than intended and may increase side effects. This requires strict medical oversight; self‑directed stacks are risky.
If you are seeing conflicting “tesamorelin dosage” advice, anchor decisions to approved guidance and your prescriber’s plan, not to forums or influencer posts.
Does dose change with weight, age or goals?
The approved 2 mg dose is not weight‑based. In real‑world settings, clinicians sometimes individualise therapy or adjust frequency off‑label, especially if IGF‑1 rises above target ranges, glucose control worsens, or side effects emerge. Any departure from approved dosing should be documented, explained, and monitored.
- Higher cardiometabolic risk: Closer glucose monitoring may be needed.
- Elevated IGF‑1: Prescribers may reassess dose, frequency, or continuation.
- Concurrent medications: Glucocorticoids can blunt GH‑axis effects; other interactions may influence response.
Side effects that may relate to dosing or IGF‑1
- Fluid retention, oedema, joint stiffness, or carpal tunnel‑like symptoms
- Injection‑site redness, itching or discomfort
- Increases in IGF‑1 that may warrant re‑evaluation
- Worsening glucose tolerance or new hyperglycaemia
- Hypersensitivity reactions (including to excipients)
Seek prompt medical advice if you notice persistent swelling, numbness/tingling in hands, significant injection‑site reactions, rash, breathing difficulty, or notable changes in blood sugar.
Who may need extra caution or should not use
- Pregnancy: Tesamorelin is not recommended in pregnancy and is contraindicated per product labelling. Discuss contraception and pregnancy plans before starting.
- Active malignancy or history of malignancy: Growth‑hormone axis considerations require specialist input.
- Pituitary disease or previous pituitary surgery/irradiation: Requires endocrinology oversight.
- Uncontrolled diabetes or significant insulin resistance: Closer monitoring is essential; alternative therapies may be considered.
- Known hypersensitivity to tesamorelin or formulation components (for example mannitol): Do not use.
Administration basics and safe technique
- Subcutaneous injection into the abdomen with site rotation to reduce local reactions
- Use the reconstitution instructions that match your specific vial strength and diluent
- Maintain cold‑chain and storage directions per your product’s label
For step‑by‑step technique and hygiene, see the injection tutorial below and use your clinic’s demonstration.
Tesamorelin in Australia: access, prescriptions and rules
- Tesamorelin is a prescription‑only medicine in Australia. Legal access is through a registered prescriber and a pharmacy.
- Importing or buying from unregulated sellers carries seizure and safety risks. Be wary of “research use” labels or products without medical supervision.
- Telehealth peptide clinics exist; assess credentials, transparency, and follow‑up monitoring before you book.
Is tesamorelin legal in Australia? | Finding a legitimate peptide clinic
Frequently asked questions
What is the standard tesamorelin dosage?
2 mg subcutaneously once daily for adults with HIV‑associated lipodystrophy, under medical supervision.
Is tesamorelin dosage weight‑based?
No. The approved dose is fixed, not by body weight.
How long should I use tesamorelin?
Duration is individual. Studies look at 26–52 weeks. Visceral fat may return toward baseline after stopping.
When should I inject tesamorelin?
Once daily at a consistent time. Evidence for morning vs evening superiority is limited; follow your prescriber.
Can I combine tesamorelin with other peptides?
Stacks may increase IGF‑1 and side effects. Do not combine without clinician oversight and lab monitoring.
Does tesamorelin help general “belly fat”?
Its approved use is for excess visceral abdominal fat in adults with HIV‑associated lipodystrophy. Other uses are off‑label.
What if I see higher IGF‑1 while on therapy?
Speak with your prescriber. They may consider re‑evaluation of dose, frequency, or continuation.
What side effects relate to dosing?
Fluid retention, joint/hand symptoms, injection‑site reactions, and glucose changes can occur. See the side effects guide and seek medical advice if concerned.
Where can I learn more?
What is tesamorelin? | Tesamorelin benefits | Results timeline
Get help with tesamorelin dosage and safety
Send your question and we’ll point you to relevant medical resources and lawful access options in Australia. We do not sell medications and this service is informational only.
Prefer to read more first? Try the Peptide Dosage Guide and Peptide Injection Guide.
Key takeaways
- Approved tesamorelin dosage is 2 mg subcutaneously once daily for HIV‑associated lipodystrophy.
- Off‑label “protocols” online vary and should not replace prescriber guidance.
- Monitoring IGF‑1 and glucose is important; dose decisions should weigh benefits and risks.
- In Australia, tesamorelin requires a prescription; avoid unregulated sources.